Overview

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Status:
NOT_YET_RECRUITING

Trial end date:
2030-01-01

Target enrollment:

Participant gender:

Summary

This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with BNT327 in participants with relapsed, progressive as well as treatment-nave, advanced/metastatic non-small cell lung cancer (NSCLC). This study will enroll adult participants with histologically or cytologically confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available).

Phase:

PHASE1

Details

Lead Sponsor:

BioNTech SE

Collaborators:

Biotheus Inc.
MediLink Therapeutics (Suzhou) Co., Ltd.

Treatments:

pembrolizumab